CGTN
Chinese President Xi Jinping has sent New Year's greetings to Chinese people of all ethnic groups, wishing happiness and good fortune for the people and prosperity for the nation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005631/en/
President Xi, also general secretary of the Communist Party of China Central Committee, extended the greetings during an inspection trip in southwest China's Guizhou Province prior to the Chinese New Year, which falls on February 12 this year.
"I'd like to extend Spring Festival blessings to people of all ethnic groups across the country. I wish everyone good health, happiness for their families, successful careers, and an auspicious Year of the Ox. I also wish our great motherland, with its beautiful mountains and rivers, much prosperity," Xi said.
During his trip, President Xi visited places including the city of Bijie and the provincial capital Guiyang, as well as a village, a residential community and a supermarket, from Wednesday to Friday.
His agenda also included a meeting with project leaders and core scientists of the Five-hundred-meter Aperture Spherical Radio Telescope (FAST) project in Guizhou. The FAST, held to be the world's most sensitive radio telescope, started operation on January 11, 2020.
On Friday's meet with scientists, President Xi called for a greater focus on scientific innovation and making it a driving force for China's development.
President Xi also spoke highly of the achievements made over the past year in Guizhou Province, as he heard a work report by the Guizhou Provincial CPC Committee and the provincial government on Friday.
He pointed out innovative development is an inevitable prerequisite of fostering China's new development paradigms and urged efforts to accelerate the integration of big data and the real economy and foster strategic merging industries.
More should be done to stimulate consumption demand and develop new consumption models, so as to unleash the consumption potential to the full, Xi said.
He demanded an effective transition from consolidating poverty alleviation achievements to promoting rural vitalization.
President Xi also expressed his great confidence in the future of the region, and wished it could make new achievements in the construction of ecological civilization.
A path of high-quality development that prioritizes ecology and highlights green development should be stuck, he added, adding that achieving common prosperity is one of the most important tasks of socialist modernization; and the government should support ethnic minorities in nurturing competitive industries and prospering their cultures.
He pointed out several aspects the government should work on to bring people benefits, including education, housing, employment, diseases prevention and control system as well as safe production.
Xi also stressed that the Red Army spent the longest time in Guizhou during the Long March, leaving behind precious spiritual treasures. And the Zunyi Conference, held in Zunyi City, is a crucial turning point in the Party's history.
The meeting focused on rectifying errors and established the correct leadership of the new Central Committee, as represented by Mao Zedong, Xi said, making it still matter today.
Original article：here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005631/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
Textron Aviation Defense Secures First Contract to Deliver Beechcraft T-6 Texan II Integrated Training System to Japan22.12.2025 02:00:00 CET | Press release
Textron Aviation Defense LLC, a Textron Inc. (NYSE:TXT) company, today announced that the company has finalized its first contract to deliver the Beechcraft T-6JP Texan II integrated training system to Japan’s Air Self-Defense Force (JASDF), in coordination with Kanematsu Corporation. The initial contract includes two Beechcraft T-6JP Texan II aircraft and instructor pilot and aircraft maintainer training materials. Deliveries of the first two aircraft are scheduled for 2029, with additional contracts anticipated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221925354/en/ The Beechcraft T-6 Texan II is designed and manufactured by Textron Aviation Defense LLC, a wholly owned subsidiary of Textron Aviation Inc. “This contract marks a pivotal step in strengthening Japan’s next-generation pilot training capabilities,” said Travis Tyler, president and CEO, Textron Aviation Defense. “We’re honored to support the Japan Air Se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom